U.S. markets closed

PDS Biotechnology Corporation (PDSB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.98+0.29 (+2.71%)
At close: 4:00PM EDT
10.98 0.00 (0.00%)
After hours: 07:50PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close10.69
Open10.65
Bid10.91 x 1400
Ask11.00 x 1100
Day's Range10.65 - 11.34
52 Week Range1.30 - 13.48
Volume674,283
Avg. Volume1,777,719
Market Cap311.464M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateAug 11, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
    GlobeNewswire

    PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

    FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 6,088,235 shares of common stock (inclusive of the 794,117 shares that were sold pursuant to the underwriter’s

  • Is PDS Biotechnology Corporation (PDSB) A Good Stock To Buy?
    Insider Monkey

    Is PDS Biotechnology Corporation (PDSB) A Good Stock To Buy?

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]

  • GlobeNewswire

    PDS Biotech Prices Public Offering of Common Stock

    FLORHAM PARK, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the pricing of its previously announced underwritten public offering of 5,294,118 shares of its common stock at a public offering price of $8.50 per share. The gross proceeds to PDS Biotech, before dedu